Brivaracetam is an innovative third-generation antiepileptic drug that selectively targets synaptic vesicle protein 2A (SV2A) with high affinity. Its excellent ability to cross the blood-brain barrier allows it to act quickly and effectively in controlling seizures. Clinical studies have consistently shown that brivaracetam provides rapid onset of action and sustained efficacy even with long-term use. It has a favorable safety profile, with notably low incidence and severity of behavioral side effects such as irritability and aggression, making it well tolerated by patients. Compared to other antiepileptic drugs, Brivaracetam stands out as one of the most effective and acceptable options, with high treatment adherence and significant improvements in patients’ quality of life. Moreover, it has demonstrated benefits beyond seizure control by enhancing cognitive functions—including attention, executive functioning, and reaction time—in people with epilepsy. Brivaracetam is widely recommended by both international and domestic clinical guidelines for epilepsy treatment. It suits a broad range of patients and is easy to use, as it requires no dose titration—the starting dose is the therapeutic dose. Qingruitian® Brivaracetam Tablets were approved for marketing in China on June 28, 2024, filling a critical gap in the domestic epilepsy treatment landscape. This important new therapy adds a powerful tool to China’s arsenal against epilepsy and brings fresh hope and expanded treatment options to patients and their families.